Do aromatase inhibitors increase cardiovascular risk? Piecing together the evidence.

[1]  P. Austin,et al.  The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer. , 2016, European journal of cancer.

[2]  H. Baker.  Extending aromatase inhibitor adjuvant therapy to 10 years. , 2016, The Lancet. Oncology.

[3]  J. Forbes,et al.  Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.

[4]  A. Ocaña,et al.  Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. , 2011, Journal of the National Cancer Institute.

[5]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[6]  Early Breast Cancer Trialists' Collaborative Group.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[7]  A. Hackshaw,et al.  Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Costantino,et al.  Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Verma,et al.  Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer , 2008, Cancer.

[10]  J. Forbes,et al.  Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Greil,et al.  Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. , 2007, Journal of the National Cancer Institute.

[12]  J. Bergh,et al.  Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. , 2005, Journal of the National Cancer Institute.

[13]  Robert B Livingston,et al.  Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. , 2005, Journal of the National Cancer Institute.

[14]  E. Perez,et al.  A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .

[15]  R. Chlebowski,et al.  Meta-analysis of vascular and neoplastic events associated with tamoxifen , 2003, Journal of General Internal Medicine.

[16]  S. Reis,et al.  Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. , 2001, Journal of the National Cancer Institute.

[17]  M. Adams,et al.  Contrasting effects of conjugated estrogens and tamoxifen on dilator responses of atherosclerotic epicardial coronary arteries in nonhuman primates. , 1997, Circulation.

[18]  L. Kuller,et al.  Coronary heart disease mortality and adjuvant tamoxifen therapy. , 1997, Journal of the National Cancer Institute.

[19]  I. Reid,et al.  The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. , 1995, The Journal of clinical endocrinology and metabolism.

[20]  L. Rutqvist,et al.  Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. , 1993, Journal of the National Cancer Institute.

[21]  C. McDonald,et al.  Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. , 1991, BMJ.

[22]  Nils Wilking,et al.  ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS , 1989, The Lancet.

[23]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[24]  R. Deitch.  After the Trial at Leicester , 1981, The Lancet.